Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in a Series B financing round. This funding is specifically allocated for the clinical development of its siRNA therapy product pipelines and the advancement of next-generation nucleic acid molecular delivery technologies. The financing round was led by Hankang Capital, with additional contributions from Delos Capital and existing investors OrbiMed and Creacion Ventures.
Innovative Focus on Cardiovascular Disease
Founded in 2021, Sirius Therapeutics is dedicated to pioneering next-generation nucleic acid therapies targeting cardiovascular diseases. The company has established a robust pipeline featuring multiple first-in-class and best-in-class differentiated products, leveraging its proprietary core technology platform designed for the development of small nucleic acid drugs.
Advancing Molecular Delivery Technology
With this new funding, Sirius Therapeutics aims to enhance its innovative capabilities in nucleic acid therapies, further positioning itself as a leader in the burgeoning field of RNA-based treatments. The company’s commitment to iteration and innovation in molecular delivery technology is expected to yield significant advancements in therapeutic options for patients with cardiovascular conditions.-Fineline Info & Tech
